This year, cancer research is moving at an exciting pace towards a real transformation. Just last month, the U.S. Food and Drug Administration approved a cancer treatment based on a biomarker rather than the body location where the cancer originates....
FDA Approves First Cancer Drug Based on Genetics… Not Tumor Location
Just last week, the U.S. Food and Drug Administration approved the cancer medicine— Keytruda® (generic name pembrolizumab)— to treat cancers that have a specific genetic mutation or biomarker. This is the first time a cancer treatment has been approved based on a biomarker rather than the body location where the…...
Attacking Metastatic Tumors in the Brain
Targeting HER3 could cripple metastatic cancers that have spread to the brain. (Bethesda, MD, June 5, 2017) Rakesh Jain, PhD, Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has discovered a novel mechanism behind…...
Highlights of ASCO 2017
Founded in 1964, the American Society of Clinical Oncology (ASCO®) is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. Each year, tens of thousands of oncology professionals, cancer researchers and patient advocates gather at The ASCO Annual Meeting to discuss the latest in…...
NFCR President Wins International Cooperation Award from the Chinese Medical Doctor Association
NFCR President receives the inaugural award from Society for Neuro-Oncology of the Chinese Medical Doctor Association for her outstanding contribution to international cooperation in March 2017. Dr. Jiang Tao, the Chairman of the Society for Neuro-Oncology of the Chinese Medical Doctor Association and the vice director of the department of…...
Strategic Media Partner
